anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Avoid contact with the eyes and skin during preparation and administration of VISUDYNE. Because of the potential to induce photosensitivity reactions, any exposed person must be protected from bright light [see Warnings and Precautions (5.1) and How Supplied/Storage and Handling (16)].

Reconstitution

Reconstitute each vial of VISUDYNE with 7 mL of Sterile Water for Injection. Each reconstituted vial provides 7.5 mL solution containing 2 mg/mL of verteporfin. Reconstituted VISUDYNE must be protected from light and used within 4 hours. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Reconstituted VISUDYNE is an opaque dark green solution.

Dilution

VISUDYNE may precipitate in saline solutions. Do not use normal saline or other parenteral solutions, except 5% Dextrose for Injection, for dilution of the reconstituted VISUDYNE. Do not mix VISUDYNE in the same solution with other drugs.

The volume of reconstituted VISUDYNE required to achieve the desired dose of 6 mg/m2 body surface area is withdrawn from the vial and diluted with 5% Dextrose for Injection to a total infusion volume of 30 mL. After dilution, protect from light and use within 4 hours.

Intravenous Infusion

The full infusion volume is administered intravenously over 10 minutes at a rate of 3 mL/minute, using an appropriate syringe pump and in-line filter. The clinical studies were conducted using a standard infusion line filter of 1.2 microns. Precautions should be taken to prevent extravasation at the injection site. If extravasation occurs, protect the site from light [see Warnings and Precautions (5.1)].
FIELD: chemical-pharmaceutical, perfume-cosmetic industry. SUBSTANCE: extractant has the following composition, wt.-%: ethyl alcohol 90.0-96.5; copper derivative of chlorophyll 0.001-0.05, and water - the rest. Extractant promotes increased yield of bioactive compounds from the raw, good safety of extracted natural compounds at extraction and the following storage. Extractant does not show toxicity, irritating and sensibilizing action and can be used in cosmetology as a solvent and component of composition. EFFECT: improved properties of extractant. 6 tbl
This invention provides a monoclonal antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. This invention also provides an isolated protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC No. HB 10916. This invention further provides an isolated nucleic acid molecule encoding a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC No. HB 10916. This invention also provides a human CD4- T cell leukemia cell line designated D1.1 having ATCC Accession No. CRL 10915 capable of constitutively providing contact-dependent helper function to B cells.
Participants will receive TV-46046 undiluted (120 mg/0.3 mL of 400 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
Telemedicine and an emerging field of novel care delivery modalities, which encompasses all forms of remote-based care. These include asynchronous (store-and-forward) and consultative care by specialists, mobile-device based care, and real-time video chat, and synchronous telemedicine. Health care services delivered remotely through telecommunications and video technology is steadily increasing as technology evolves and access becomes more widely available. The increasing availability of personal technology - 89% Americans have internet access, 77% are online daily - offers patients and clinicians the opportunity to utilize real-time virtual communication to enhance access for patients when transportation challenges, schedules, or physical disability make office visits difficult in any geography. With the increased use of technology in healthcare, much emphasis has been placed on telemedicine as it can extend the services of providers to remote locations and overcome the barrier of proximity. This expands access to care and has the potential of making healthcare services more convenient for many patients who otherwise might suffer access barriers.

It is increasingly evident that telehealth can improve access to healthcare services and specialists; prevent unnecessary delays in receiving care, and facilitate coordinated care and interprofessional collaboration. The World Health Organization affirms the efficacy of telehealth as an effective service delivery model for professionals.

Telemedicine has been shown to improve health outcomes, increase communication with providers, increase access to high-quality service, decrease travel time, decrease missed appointments, decrease wait time, decrease repeat admissions, increase self-awareness, increase medication adherence, and increase self-monitoring of chronic conditions. The technical quality of telehealth consultation (e.g. audio and visual quality of a videoconference) has been shown to influence clinicians' willingness to practice in this manner and the satisfaction of users. A recent systematic review on patient satisfaction with telemedicine found that patient satisfaction can be associated with the modality of telehealth, but factors of effectiveness and efficiency are mixed. Telehealth is a feasible option to expand practices to remote areas without having to relocate or expand. Understanding the perceived relative value of different modes of healthcare services may help to shape the use of virtual or remote healthcare technologies. System learning that demonstrates the value of different types of "visits" for the system and the patient is essential.
Sepsis is caused by the body's dysregulated response to infection, which can lead to multiorgan injury and death. Patients with sepsis may develop acute cardiac dysfunction, termed septic cardiomyopathy, which is a global but reversible dysfunction of both sides of the heart. This narrative review discusses the mechanistic changes in the heart during septic cardiomyopathy, its diagnosis, existing treatment options regarding severity and course, and emerging treatment approaches. Although no standardized definition for septic cardiomyopathy exists, it is described as a reversible myocardial dysfunction that typically resolves within 7 to 10 days. Septic cardiomyopathy is often diagnosed based on electrocardiography, cardiac magnetic resonance imaging, biomarkers, and direct invasive and noninvasive measures of cardiac output. Presently, the treatment of septic cardiomyopathy is similar to that of sepsis, primarily focusing on acute interventions. Treatments for cardiomyopathy often include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics. However, because of profound hypotension in sepsis, many cardiomyopathy treatments are contraindicated in patients with septic cardiomyopathy. Substantial efforts have been made to study the pathophysiological mechanisms and diagnostic options; however, the lack of a uniform definition for septic cardiomyopathy is challenging for physicians when considering treatments. Another challenge for physicians is that the treatment for septic cardiomyopathy has only focused on acute intervention, whereas the treatment for other cardiomyopathies has been provided on a long-term basis. A better understanding of the underlying mechanisms of septic cardiomyopathy may contribute to the development of a unified definition of the condition and novel treatment options.
Methods: Patients will undergo percutaneous needle biopsies from either primary or metastatic sites to obtain tumor tissue. Patients in whom sufficient tumor mRNA has been amplified by PCR to transfect the assigned dendritic cell dose will undergo leukapheresis and peripheral blood mononuclear cells will be cultured in vitro for 7 days with GM-CSF and IL-4 to generate precursor derived dendritic cells. Dendritic cells will then be cryopreserved for later use. On the day the patient returns to receive his infusion (weeks 0, 2, and 4) the dendritic cells will be thawed, reconstituted, and transfected with amplified total tumor mRNA. Patients will receive a total of 3 treatments consisting of combined I.V. and I.D. injections, each on study week 0, 2, and 4. Repeat leukapheresis will be performed 2 weeks after the last dose to determine immune function. PSA levels will be measured prior to the start of treatment and 2 weeks following the last infusion. Patients who do not receive therapy due to a failure to produce sufficient RNA or dendritic cells will be replaced in order to assess toxicity.

Data Analysis: 1. To determine the short and long term toxicities associated with administration of tumor RNA dendritic cells in patients with metastatic prostate cancer. 2. To determine feasibility of dendritic cell vaccine generation according to the proportion of patients for whom sufficient cells are generated to provide treatment. 3. To determine the cellular immune response to intravenous infusion of tumor RNA dendritic cells. 4. To measure the PSA response of patients with metastatic prostate cancer to intravenous infusion of tumor RNA dendritic cells.
Cosmetic and/or dermatological composition for treating keratinic fibres comprises a carrier, at least one 2-electron oxidoreductase enzyme, at least one substrate for the enzyme, and at least one nonionic fatty sucronamide term not defined. Preferably the enzyme is an animal, microbial or recombinant uricase and is present in an amount of 0.01-20 (preferably 0.1-5) wt.%. The substrate is selected from uric acid and its salts and is present in an amount of 0.01-20 (preferably 0.1-5) wt.%. The nonionic fatty sucronamide is selected from N-substituted aldonamides and polyhydroxylated fatty acid amides. The N-substituted aldonamides are selected from: (1) N-alkyl lactobionamides, N-alkyl maltobionamides, N-alkyl cellobionamides, N-alkyl mellibionamides or N-alkyl gentiobionamides mono- or disubstituted by an 8-18C aliphatic hydrocarbon group (optionally containing heteroatoms), an aromatic hydrocarbon group or an alicylic group; (2) N-lactobionyl, N-maltobionyl, N-mellibionyl, N-cellobionyl and N-gentiobionyl amino acid esters, where the amino acid is Ala, Val, Gly, Lys, Leu, Arg, Asp, Glu, Thr, Ser, Cys, His, Tyr, Met, beta -alanine, sarcosine, gamma-aminobutyric acid, and ornithine. Used for bleaching human hair by applying the composition, optionally containing an auxiliary oxidising agent, and then rinsing; for dyeing human hair by applying a composition as above containing an oxidation dye precursor and optionally a coupler; for permanent waving of human hair by applying a reducing composition, putting the hair under tension, optionally rinsing the hair, applying a composition as above, and optionally rinsing the hair.
The invention relates to a traditional Chinese medicine preparation for treating dysmenorrhea. The traditional Chinese medicine preparation is prepared from angelica sinensis, red dates, herba lycopi, pericarpium citri reticulatae, agilawood, charred typhae pollen, leonurus, corydalis tuber processed with vinegar, peach kernels, costus roots, ginger, pseudo-ginseng powder, radix rehmanniae preparata, fried jasmine and the root of three-nerved spicebush. The traditional Chinese medicine preparation provided by the invention has the functions of managing qi, activating blood circulation, reliving urgency and pain, soothing liver-qi stagnation, regulating menstruation, relieving pain, promoting the circulation of qi, dispersing blood stasis, reinforcing qi, nourishing blood and the like. After the traditional Chinese medicine preparation is taken, growth of endometrium is inhibited, the menstrual blood volume is reduced, so that the activity of womb is weakened, the tension and contractility of womb are reduced, the activity of light streptokinase of myosin is inhibited, and uterine myometrium is promoted to relax, so that the purpose of quickly relieving pain is achieved. Microcirculation in a human body is adjusted and the endocrine system restores the self-adjusting function to reach balance between yin and yang, so that qi-blood circulation is smooth, blood flow in cervix uteri is not blocked, damaged veins are repaired, and main and collateral channels are unobstructed, symptoms of stomachache, headache, vexation, lassitude, pale face and the like are thoroughly removed. Finally, dysmenorrhea is thoroughly cured.
Approximately 15-20% of global cancer cases are attributed to virus infections. Oncoviruses employ various molecular strategies to enhance replication and persistence. Human cytomegalovirus (HCMV), acting as an initiator or promoter, enables immune evasion, supporting tumor growth. HCMV activates pro-oncogenic pathways within infected cells and direct cellular transformation. Thus, HCMV demonstrates characteristics reminiscent of oncoviruses. Cumulative evidence emphasizes the crucial roles of EZH2 and Myc in oncogenesis and stemness. EZH2 and Myc, pivotal regulators of cellular processes, gain significance in the context of oncoviruses and HCMV infections. This axis becomes a central focus for comprehending the mechanisms driving virus-induced oncogenesis. Elevated EZH2 expression is evident in various cancers, making it a prospective target for cancer therapy. On the other hand, Myc, deregulated in over 50% of human cancers, serves as a potent transcription factor governing cellular processes and contributing to tumorigenesis; Myc activates EZH2 expression and induces global gene expression. The Myc/EZH2 axis plays a critical role in promoting tumor growth in oncoviruses. Considering that HCMV has been shown to manipulate the Myc/EZH2 axis, there is emerging evidence suggesting that HCMV could be regarded as a potential oncovirus due to its ability to exploit this critical pathway implicated in tumorigenesis.
A dialysis system includes include a home dialysis machine and a home gateway device in communication with a cloud-based application via a connected health system. The gateway device has voice recognition capabilities. A user can provide spoken information to the gateway device, and the gateway device can cause one or more actions to be performed. The gateway device may cause a dialysis function to be performed by the dialysis machine, or data to be input into the dialysis machine. The gateway device can also communicate with one or more other systems (e.g., remote systems) via the cloud-based application. In some examples, the cloud-based application can communicate with an order management system to allow the user to order medical supplies (e.g., for use with the dialysis machine) via the gateway device. The gateway device can provide two-way conversational capability (e.g., back and forth communication) between the user and the gateway device.
PURPOSE: Septoplasty and rhinoplasty are common otolaryngological procedures, often combined as septorhinoplasty (SRP), offering aesthetic and functional benefits. These surgeries are believed to potentially risk postoperative infections due to natural bacterial flora in the nares. This study evaluates the effectiveness of prophylactic antibiotics in reducing post-surgical infection complications.
MATERIALS AND METHODS: A systematic review was conducted using PubMed, Cochrane, and Web of Science, adhering to PRISMA guidelines, focusing on antibiotic use in septoplasty, rhinoplasty, and SRP. The study included randomized control trials, single/double-blind studies, retrospective chart reviews, and prospective cohort studies, excluding pediatric, non-human research, or studies with inaccessible data. Postoperative infection rates were analyzed utilizing R software as a form of Statistic.
RESULTS: From 697 articles, 15 studies were chosen for meta-analysis, involving 2225 patients, with 1274 receiving prophylactic antibiotics and 951 as controls. The meta-analysis indicated an odds ratio of 0.65 (95 % CI: [0.23, 1.89]), showing no significant protective effect of prophylactic antibiotics.
DISCUSSION: The study found no significant infection rate reduction with prophylactic antibiotic use. Notable were inconsistencies in study designs, antibiotic administration timing, and varied surgical practices. Antibiotic use risks were considered. Study limitations include potential biases and the retrospective nature of many studies.
CONCLUSIONS: This review and meta-analysis found no substantial evidence supporting prophylactic antibiotics' effectiveness in reducing postoperative infection rates in septoplasty, rhinoplasty, and SRP, indicating a need to reevaluate practices and develop evidence-based guidelines. Future research should focus on comprehensive, randomized control studies, covering both preoperative and postoperative stages.
Binge drinking is rising among aged adults (>65 years of age), however the contribution of alcohol misuse to neurodegenerative disease development is not well understood. Both advanced age and repeated binge ethanol exposure increase neuroinflammation, which is an important component of neurodegeneration and cognitive dysfunction. Surprisingly, the distinct effects of binge ethanol exposure on neuroinflammation and associated degeneration in the aged brain have not been well characterized. Here, we establish a model of intermittent binge ethanol exposure in young and aged female mice to investigate the effects of advanced age and binge ethanol on these outcomes. Following intermittent binge ethanol exposure, expression of pro-inflammatory mediators (tnf-α, il-1β, ccl2) was distinctly increased in isolated hippocampal tissue by the combination of advanced age and ethanol. Binge ethanol exposure also increased measures of senescence, the nod like receptor pyrin domain containing 3 (NLRP3) inflammasome, and microglia reactivity in the brains of aged mice compared to young. Binge ethanol exposure also promoted neuropathology in the hippocampus of aged mice, including tau hyperphosphorylation and neuronal death. We further identified advanced age-related deficits in contextual memory that were further negatively impacted by ethanol exposure. These data suggest binge drinking superimposed with advanced age promotes early markers of neurodegenerative disease development and cognitive decline, which may be driven by heightened neuroinflammatory responses to ethanol. Taken together, we propose this novel exposure model of intermittent binge ethanol can be used to identify therapeutic targets to prevent advanced age- and ethanol-related neurodegeneration.
A three-session face-to-face intervention using Motivational Interviewing with a facilitator; to increase Pre-Exposure Prophylaxis (PrEP) uptake. Pre-post-post evaluations after each session will be administered. Participation will last 150 days from the start to the last follow-up.
PROBLEM TO BE SOLVED: To provide an early detection method of a high quality for an ophthalmologic disease and a preventive medical care.SOLUTION: A server of an ophthalmologic inspection support system of one embodiment comprises a medical information storage device for storing medical information of each patient and a management device for managing the medical information storage device. A plurality of clients can communicate with the management device. A relative information storage part previously stores relative information associated with the medical information of a predetermined item and an inspection condition of the ophthalmologic inspection. An inspection condition acquisition part acquires the inspection condition associated with the medical information corresponding to the patient information transmitted from the client. A control part of the client performs a control based on the acquired inspection condition. The control part of the management device receives the medical information including the inspection data of a patient eye transmitted together with the patient information from the client so as to be stored in the medical information storage device. A first update part of the management device statically processes the medical information inside the medical information storage device and updates the relative information.SELECTED DRAWING: Figure 2
PURPOSE:To obtain a sustained release pharmaceutical preparation capable of releasing a definite amount of medicine over a long period. CONSTITUTION:This sustained release pharmaceutical preparation has plural layers containing a complex of a medicine and a biodegradable organic substance, e.g. a polymer of lactic acid, glycolic acid or lactone or a copolymer thereof or collagen and ceramics and all layers except outermost layer of the plural layers are covered by the outside layer and in a ratio of the complex in each layer of the plural layers to ceramic, the ratio of the outside layer is smaller than that of the inner layer. As the ceramics, a material having biological affinity, e.g. calcium phosphate-based compound, CaO.P2O5-based glass, alumina or zirconia is preferably used. Since a ratio of the complex is small in the outside layer having large contact area with the biological tissue, decomposition of an organic substance occurs slowly. Since a ratio of the complex is large regardless of small contact area with biological tissue also in the inner layer, the organic substance is readily decomposed and as a result, release amount of the medicine becomes definite in each layer.
PROBLEM TO BE SOLVED: To obtain a readily handleable permanent waving composition having good permeability into hair and small liquid dropping inclination in treatment of hair and excellent in finishing property. SOLUTION: This composition contains one or more kinds of surfactants selected from an anionic surfactant, an amphoteric surfactant and a semipolar surfactant and a higher fatty acid (e.g. isostearic acid) in an aqueous solution containing a reducing agent (e.g. thioglycolic acid) and an alkali agent (e.g. monoethanolamine). The anionic surfactant, the amphoteric surfactant and the semipolar surfactant are blended at a weight ratio of (4/6) to (6/4) or in an amount of 0.1-20wt.% based on weight of total composition and the higher fatty acid is blended in an amount of 0.01-5wt.% based on weight of total composition. Further, additives such as urea, silicone, amino acid, oil content, a metal ion sealing agent, a perfume and a pigment are properly blended therewith and the blend is controlled to pH6-2 to provide the objective composition.  The composition is used as the first agent for a cold two bath type, heating two bath type or a heat-generating two bath type prepared when used.
Although mRNA vaccines for COVID-19 are highly beneficial and are recommended for patients with kidney disease, adverse reactions in some patients after vaccination have been problematic. Various vasculitis and renal disorders have been reported after vaccination; however, a causal relationship has not yet been identified. In this report, we describe a case of rapidly progressive glomerulonephritis that developed after SARS-CoV-2 vaccination, in which both anti-glomerular basement membrane (anti-GBM) and myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) were present. The patient's renal biopsy showed that of the 48 glomeruli in total, four showed global sclerosis and none showed segmental sclerosis. The biopsy showed 11 cellular glomerular crescents and 5 fibrocellular glomerular crescents. Renal function improved with steroids, rituximab, and plasma exchange. Approximately 9 months later, MPO-ANCA was again elevated, and the pulmonary lesions worsened, again requiring multidisciplinary treatment. This case suggests that caution should be exercised in the development of double-positive disease after vaccination, and that long-term observation may be necessary because of the possibility of relapse.
After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.